CASE REPORT

Life-threatening hemorrhage from acquired hemophilia A as a presenting manifestation of prostate cancer

Chirag Sheth, MD*, Amandeep Gill, MD and Sumeet Sekhon, MD

Department of Internal Medicine, San Joaquin General Hospital, French Camp, CA, USA

Acquired factor VIII deficiency (acquired hemophilia A) is a rare immune-mediated disease, which can affect any clotting factor, with factor VIII (fVIII) being the most common target of antibody formation. The annual incidence is 1–4 per million populations with a mortality rate of 8–22% in affected patients when left untreated (1–3). About 50% of these cases are idiopathic, while the rest are associated with autoimmune diseases, malignancies, pregnancy, medications, or dermatologic disease (1–6). Among cancer patients, AHA has been associated with solid tumors or hematologic malignancies (7).

The diagnosis is often made in the presence of prolonged activated partial thromboplastin time (aPTT) with normal prothrombin time (PT). Mixing studies confirm the presence of an inhibitor. Management of this condition begins with attempts to arrest an acute bleed based on the site and severity of bleeding and inhibitor titer (8). The next priority is eradication of the fVIII antibodies using immunosuppressive therapies. We report the case of a 66-year-old male who presented with spontaneous right thigh hematoma with prolonged activated partial prothrombin time and normal prothrombin time. Mixing studies confirmed the presence of an inhibitor. Further investigation for the underlying etiology of acquired hemophilia A leads to diagnosis of prostate cancer. Treatment consisted of bypassing agents including activated factor VII and activated prothrombin plasma concentrate to arrest the bleeding. Steroids and cyclophosphamide were added to suppress the fVIII inhibitors. Concomitant treatment of locally advanced prostate cancer with chemotherapy confirmed the eradication of the inhibitors. To our knowledge, this is the first reported case of prostate cancer diagnosed and treated simultaneously with acquired hemophilia A resulting in favorable patient outcome.

Keywords: acquired hemophilia A; prostate cancer; activated factor VII; activated prothrombin plasma concentrate

*Correspondence to: Chirag Sheth, 500 W Hospital Road, French Camp, CA 95231, Email: csheth@sjgh.org

Received: 31 May 2016; Revised: 14 July 2016; Accepted: 15 July 2016; Published: 7 September 2016

Case report

The patient was a 66-year-old male with a medical history of schizophrenia, who presented with a 1 month history of inability to ambulate secondary to right thigh pain and swelling that progressively worsened over 2 weeks. There was no history of trauma to the leg or intravenous drug abuse. The patient denied taking any prescribed or over-the-counter medications. There was no personal or family history of bleeding disorders. Physical examination was remarkable for hard and swollen right mid-thigh area. Computed tomography (CT) scan of right lower extremity showed heterogeneous enlargement of the musculature of the anterior compartment of the right thigh (Fig. 1) and an enlarged prostate (Fig. 2). Concern for compartment syndrome led to immediate surgical intervention and a large hematoma was evacuated from the right thigh. Tissue biopsy confirmed the diagnosis of hematoma. Postoperatively, the patient started bleeding profusely from the incision site, requiring multiple units of packed red blood cell transfusions and fresh frozen plasma for hemostasis as an emergency measure. Laboratory analysis revealed that aPTT was prolonged at 65 s (reference range 25–38 s) with normal PT 12.8 (reference range 11.7–13.9 s).
and International normalized ratio (INR) 1.0 (reference range 0.9–1.1). Further investigation with mixing studies revealed time-dependent inhibitor of FVIII. FVIII inhibitor level was elevated at 140.9 Bethesda units (reference range 0.4–4) and FVIII activity was <1% of normal (reference range 50–180%), thus establishing a diagnosis of acquired FVIII deficiency. After confirmation of the diagnosis, hemostatic FVIII inhibitor bypassing agent recombinant activated factor VIIa (rfVIIa) was infused, however; the patient experienced recurrent bleeding requiring activated prothrombin complex concentrate (aPCC) to stabilize the bleed. Prednisone 1 mg/kg/day and cyclophosphamide 2 mg/kg/day were initiated in addition to supportive care to suppress the production of inhibitor.

Further workup to diagnose the underlying etiology revealed significantly elevated prostate-specific antigen (PSA) level at 131 ng/ml (reference range 0.05–4 ng/ml), and a diagnosis of prostate cancer was made (11, 12). Serum human immunodeficiency virus, hepatitis panel, erythrocyte sedimentation rate, and antinuclear antibody were negative. In addition to normal alkaline phosphatase, CT scan of chest, abdomen, and pelvis with intravenous contrast did not show any evidence of bony metastasis or lymph node involvement. In light of high bleeding risk and patient’s overall critical condition, decision was made to treat locally advanced prostate cancer with hormonal therapy alone. The patient was started on luteinizing hormone-releasing hormone analogue leuprolide and antiandrogen therapy with bicalutamide. The patient had a prolonged hospital course complicated by hemorrhagic shock, acute upper gastrointestinal bleeding secondary to severe erosive esophagitis, and small bowel obstruction. The patient continued to improve and was eventually discharged to a skilled nursing facility after 35 days of hospitalization.

Three weeks after the discharge, the patient was readmitted due to minor bleeding from the surgical wound, requiring one dose of aPCC and local application ofaminocaproic acid. The patient was discharged in stable condition after 2 days of inpatient stay. The patient had a follow-up positron emission tomography–computed tomography (PET-CT) scan with F-18 fludeoxyglucose (FDG), which confirmed an irregularly enlarged prostate gland 5.5 cm × 5 cm (compared to 7.6 cm × 7.0 cm, 7 months ago) extending into inferior portion of urinary bladder, suggesting prostate cancer. There were not any hypermetabolic abnormalities elsewhere suggesting evidence of metastasis.

At 3 months follow-up, no further hemorrhagic episodes were noted. The patient’s aPTT was 30.6 s and the PSA level (1.3 ng/ml) had normalized. FVIII inhibitor was non-detectable and FVIII activity level had increased to 170% (Table 1). The patient continues to remain asymptomatic with regular follow up in our outpatient hematology and oncology clinic.

**Discussion**

AHA is an extremely rare condition with age distribution of inhibitors being typically biphasic with a small peak between ages 20 and 30 years (due to postpartum inhibitors) and a major peak in patients of ages 68–80 years. The diagnosis of AHA is based on clinical history and laboratory investigations. It is distinct from classical inherited hemophilia, which is caused by deficiency of FVIII or factor IX that usually presents with hemarthrosis, whereas patients with AHA often present with soft tissue,
skin, muscle, or mucus membrane bleeds (1, 5, 7). Our patient presented with right thigh intramuscular hematoma that occurred spontaneously. Prolonged aPTT in the setting of skin or soft tissue bleeding should alert clinicians about the presence of an inhibitor to fVIII. Mixing studies, including Bethesda assay, confirm and quantify the presence of fVIII inhibitor, enabling the clinician to start immediate treatment.

Even though more than half of the cases are idiopathic, workup should target possible underlying etiologies such as malignancies, infections, and autoimmune disorders, as well as offending medications. AHA is associated with malignancies in 7–15% of cases, with the majority related to solid tumors. Our patient had significantly elevated PSA level (131 ng/ml) consistent with diagnosis of prostate cancer (11, 12). Treatment generally consists of achieving hemostasis, suppression of fVIII inhibitors, and treatment targeted at the underlying etiology, such as malignancy in our case. The cure of the associated disease sometimes leads to the eradication of the factor inhibitor (13).

The three-step approach for the management of patients with AHA and bleeding diathesis is presented in the following.

Hemostasis can be achieved by two approaches: the use of bypassing agents or raising fVIII level depending on the site and severity of bleeding. Two bypassing agents, rFVIIa and aPCC, have been used as first-line treatment.

Table 1. Time course of hemostasis parameters and serum PSA

| Labs            | Reference range | On admission | One month follow-up | Three months follow-up |
|-----------------|-----------------|--------------|---------------------|------------------------|
| FVIII activity  | 50–180%         | <1%          | 50%                 | 170%                   |
| FVIII inhibitor level | ≤0.4 | 141         | 34 Non-detectable |                        |
| aPTT            | 25–38 s         | 65           | 32                  | 31                     |
| PSA             | 0.05–4.00       | 131          | 3.8                 | 1.3                    |

Fig. 3. Coagulation cascade. Factor VIII inhibitor blocking intrinsic pathway (shown by black box); mechanism of action of recombinant activated factor VII (shown by yellow blocks), which binds with activated platelets to activate factor X and generate factor Xa; activated prothrombin complex concentrate contains activated factor VII and inactivated factors II, IX, and X (shown by the symbol ★).
rfVIIa binds directly with activated platelets to activate factor X to produce factor Xa, activating common pathway, while aPCC contains four different coagulation factors, mostly activated factor VII and inactivated factors II, IX, and X (14, 15). Both products bypass the need for fVIII and activate common pathway to generate clot formation (Fig. 3). Retrospective studies have shown the overall efficacy rate for rfVIIa at 88% and for aPCC around 86% (16, 17). Patients with life-threatening bleeding and a very high titer level should be managed by rfVIIa or aPCC. In our patient, we were unable to achieve adequate hemostasis with rfVIIa; therefore, aPCC was used successfully to attain complete hemostasis (16–19).

Minor bleeding episodes with low titer level can be controlled by human or porcine fVIII concentrate or desmopressin, either alone or in combination. Fresh frozen plasma is often ineffective because of a very low level of fVIII concentration.

Suppression and eradication of fVIII inhibiting antibodies is achieved through immunosuppressive therapy as well as targeted therapy at underlying etiology. Immunosuppressive therapy includes steroids, cytotoxic drugs (e.g., cyclophosphamide, azathioprine, and rituximab), high-dose intravenous immunoglobulin, and immunoadsorption (9, 10, 20–22). Prednisone plus cyclophosphamide is considered a first-line treatment of AHA. The majority of evidence comes from case reports or retrospective studies. In the EACH2 study, stable complete remission was achieved with steroids plus cyclophosphamide in 70% of patients, compared to steroids alone (48%) or rituximab-based regimens (59%) (23). Only one randomized prospective trial on this patient population as well as few case series showed that oral steroid in combination with oral cyclophosphamide for 5 weeks was successful in achieving a complete remission (10). In our case, we used a combination of prednisone 1 mg/kg/day and cyclophosphamide 2 mg/kg/day for 5 weeks. Once the fVIII level was normalized and inhibitors were undetectable, cyclophosphamide was stopped and prednisone was tapered off. Concomitant treatment of locally advanced prostate cancer with hormonal therapy also improved the patient’s survival.

In conclusion, this case demonstrates the importance of history taking, for instance, sudden onset of bleeding especially into the skin, soft tissues, mucus membranes, or muscles with no prior personal or family history of bleeding episodes (24) and quick analysis of coagulation panel with isolated prolonged aPTT and normal PT, as a delay in diagnosis and treatment can lead to life-threatening bleeding. As illustrated by our patient, concomitant treatment of underlying etiology, in our case prostate cancer, along with immunosuppressive therapy resulted in a favorable outcome.

Conflict of interest and funding

The authors have not received any funding or benefits from industry or elsewhere to conduct this study.

References

1. Green D, Lehner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200–3.
2. Bossi P, Cabane J, Ninet J, Dhotre R, Hanslik T, Chosidow O. Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med 1998; 105: 400–8.
3. Yee TT, Pasi KJ, Lilley PA, Lee CA. Factor VIII inhibitors in haemophiliacs: A single-centre experience over 34 years, 1964–97. Br J Haematol 1999; 104: 909–14.
4. Solymosi S. Postpartum acquired factor VIII inhibitors: Results of a survey. Am J Haematol 1998; 59: 1–4.
5. Arruda VR, High KA. Coagulation disorders. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, (eds.). Harrison's principles of internal medicine, p. 973–82. New York: McGraw Hill Medical; 2011.
6. Boggio LN, Green D. Acquired hemophilia. Rev Clin Exp Hematol 2001; 5: 389–404.
7. Reeves BN, Key NS. Acquired hemophilia in malignancy. Thromb Res 2012; 129(Suppl 1): S66–8. doi: http://dx.doi.org/10.1016/S0049-3848(12)70019-1.
8. Green D. The management of acquired hemophilia. Haemophilia 2006; 12(Suppl 5): 32–6.
9. Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost 2007; 5: 893–900.
10. Green D, Rademaker AW, Briet E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993; 70: 753–7.
11. Gerstenbluth RE, Setefl AD, Hampel N, Oefelein MG, Resnick MI. The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng/ml) in predicting prostate cancer: Is biopsy always required? J Urol 2002; 168(5): 1990–3.
12. Jang JY, Kim YS. Is prostate biopsy essential to diagnose prostate cancer in the older patient with extremely high prostate specific antigen? Korean J Urol 2012; 53(2): 82–6.
13. Shurafa M, Raman S, Wollner I. Disappearance of factor VIII antibody after removal of primary colon adenocarcinoma. Am J Hematol. 1995; 50: 149–50.
14. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost 2001; 85(6): 958–65.
15. Turecek PL, Varadi K, Gritsch H, Schwarz HP. FEIBA: Mode of action. Haemophilia 2004; 10(Suppl 2): 3–9.
16. Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired hemophilia with recombinant activated FVII: A critical appraisal. Haemophilia 2007; 13: 451–61.
17. Sallah S. Treatment of acquired hemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10: 169–73.
18. Goudemand J. Treatment of bleeding episodes occurring in patients with acquired haemophilia with FEIBA: The French experience. Haemophilia 2004; 10(Suppl 3): abstract PO14.
19. Hay CRM, Negrier C, Ludlam CA. The treatment of bleeding in acquired hemophilia with recombinant factor VIIa: A multicenter study. Thromb Haemost 1997; 78: 3–7.
20. Shaffer LG, Phillips MD. Successful treatment of acquired hemophilia with oral immunosuppressive therapy. Ann Intern Med 1997; 127: 206–9.
21. Söhngen D, Specker C, Bach D, Kuntz BM, Burk M, Aul C. Acquired factor VIII inhibitors in nonhemophilic patients. Ann Hematol 1997; 74: 89–93.

22. Lian EC, Larcada AF, Chiu AY. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989; 110: 774–8.

23. Collins P, Baudo F, Knoebl P, Lévesque H, Nemes L, Pellegrini F. Immunosuppression for acquired hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2). Blood 2012; 120(1): 47–55.

24. Kessler CM, Knöbl P. Acquired haemophilia: An overview for clinical practice. Eur J Haematol 2015; 95(Suppl 1): 36–44.